- Home
- CLLS vs NPCT Comparison
CLLS vs NPCT Comparison
Compare CLLS & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | NPCT |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.2M | 294.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | NPCT |
|---|---|---|
| Price | $3.84 | $10.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 31.7K | ★ 143.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $9.77 |
| 52 Week High | $5.48 | $11.31 |
Technical Indicators
Market Signals| Indicator | CLLS | NPCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 69.32 |
| Support Level | $3.41 | $10.58 |
| Resistance Level | $4.54 | $10.73 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 50.00 | 67.86 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.